Alnylam Pharmace. Stock
Alnylam Pharmace. Stock
The Alnylam Pharmace. stock is trending slightly upwards today, with an increase of €0.65 (0.350%) compared to yesterday's price.
With 51 Buy predictions and not a single Sell prediction Alnylam Pharmace. is an absolute favorite of our community.
With a target price of 427 € there is potential for a 126.95% increase which would mean more than doubling the current price of 188.15 € for Alnylam Pharmace..
Our community identified positive and negative aspects for Alnylam Pharmace. stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Alnylam Pharmace. stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
AI-generated
Pros and Cons of Alnylam Pharmace. in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alnylam Pharmace. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alnylam Pharmace. | 0.350% | 5.189% | -31.494% | -48.952% | -44.658% | 11.210% | 12.986% |
| Ligand Pharmaceuticals | - | 3.968% | -6.429% | 123.932% | 57.831% | 329.508% | 184.103% |
| United Therapeutics | -0.580% | 1.359% | -3.365% | 75.379% | 8.191% | 115.424% | 154.011% |
| Ionis Pharmaceuticals Inc. | 1.990% | 2.294% | -35.011% | 35.377% | -30.459% | 30.950% | 43.169% |
Comments
Alnylam Pharmaceuticals (ALNY) had its price target lowered by Truist Financial Corporation from $410.00 to $315.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals (ALNY) had its price target lowered by Citigroup Inc. from $380.00 to $340.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals (ALNY) was upgraded by Raymond James Financial, Inc. from "outperform" to "strong-buy". They now have a $420.00 price target on the stock.
Show more
Ratings data for ALNY provided by MarketBeat